The safety of serotonin–noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1077|30|3|143-151

ISSN： 0885-6222

Source： Human Psychopharmacology: Clinical And Experimental (Electronic), Vol.30, Iss.3, 2015-05, pp. : 143-151

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy

By Alwan Sura   Friedman Jan M.  

CNS Drugs, Vol. 23, Iss. 6, 2009-05 ,pp. : 493-509

Adis International

Access to resources Recommend Favorite

The Economic Impact of Introducing Serotonin-Noradrenaline Reuptake Inhibitors into the Brazilian National Drug Formulary: Cost-Effectiveness and Budget-Impact Analyses

By Machado Márcio   Iskedjian Michael  

PharmacoEconomics, Vol. 25, Iss. 11, 2007-01 ,pp. : 979-990

Adis International

Access to resources Recommend Favorite

Selective Serotonin Reuptake Inhibitors in Pregnancy

By  

Current Medicinal Chemistry, Vol. 19, Iss. 27, 2012-09 ,pp. : 4554-4561

Bentham Science Publishers

Access to resources Recommend Favorite

Use of selective serotonin reuptake inhibitors during pregnancy and breastfeeding has both benefits and risks

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 22, Iss. 3, 2006-03 ,pp. : 22-26

Adis International

Access to resources Recommend Favorite

Duloxetine: a serotonin-noradrenaline re-uptake inhibitor for the treatment of stress urinary incontinence

By Zinner Norman R  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 9, 2003-09 ,pp. : 1559-1566

Informa Healthcare

Access to resources Recommend Favorite